PMID- 21159705
OWN - NLM
STAT- MEDLINE
DCOM- 20110630
LR  - 20110316
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 17
IP  - 2
DP  - 2011 Apr
TI  - Economic impact of enoxaparin after acute ischemic stroke based on PREVAIL.
PG  - 150-7
LID - 10.1177/1076029610389026 [doi]
AB  - The efficacy and safety of low-molecular-weight heparins (LMWHs) versus 
      unfractionated heparin (UFH) has been demonstrated for the prevention of venous 
      thromboembolism (VTE) after acute ischemic stroke. Few data exist regarding the 
      economic impact of LMWHs versus UFH in this population. A decision-analytic model 
      was constructed using clinical information from the Prevention of VTE after Acute 
      Ischemic stroke with LMWH Enoxaparin (PREVAIL) study, and drug costs and mean 
      Centers for Medicare & Medicaid Services event costs. When considering the total 
      cost of events and drugs, enoxaparin was associated with cost-savings of $895 per 
      patient compared with UFH ($2018 vs $2913). Findings were retained within the 
      univariate and multivariate analyses. From a payer perspective, enoxaparin was 
      cost-effective compared with UFH in patients with acute ischemic stroke. The 
      difference was driven by the lower clinical event rates with enoxaparin. Use of 
      enoxaparin may help to reduce the clinical and economic burden of VTE.
FAU - Pineo, Graham
AU  - Pineo G
AD  - Department of Medicine, University of Calgary, Calgary, Canada. 
      Graham.Pineo@albertahealthservices.ca
FAU - Lin, Jay
AU  - Lin J
FAU - Stern, Lee
AU  - Stern L
FAU - Subrahmanian, Tarun
AU  - Subrahmanian T
FAU - Annemans, Lieven
AU  - Annemans L
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101215
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anticoagulants/*administration & dosage
MH  - Brain Ischemia/*drug therapy
MH  - Child
MH  - Costs and Cost Analysis
MH  - *Decision Making, Computer-Assisted
MH  - Enoxaparin/*administration & dosage
MH  - Female
MH  - Humans
MH  - Male
MH  - Medicare
MH  - Middle Aged
MH  - *Models, Biological
MH  - Stroke/*drug therapy
MH  - United States
MH  - Venous Thromboembolism/*prevention & control
EDAT- 2010/12/17 06:00
MHDA- 2011/07/01 06:00
CRDT- 2010/12/17 06:00
PHST- 2010/12/17 06:00 [entrez]
PHST- 2010/12/17 06:00 [pubmed]
PHST- 2011/07/01 06:00 [medline]
AID - 1076029610389026 [pii]
AID - 10.1177/1076029610389026 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2011 Apr;17(2):150-7. doi: 10.1177/1076029610389026. 
      Epub 2010 Dec 15.